Christos Papageorgiou, MD - MU Health Care

Dr. Christos Papageorgiou

Claim this profile

MU Health - University Hospital/Ellis Fischel Cancer Center

Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
26 drugs studied

Area of expertise

1Breast Cancer
Christos Papageorgiou has run 10 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
HER2 negative
2Breast Cancer
Christos Papageorgiou has run 7 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage IV

Affiliated Hospitals

Image of trial facility.
MU Health - University Hospital/Ellis Fischel Cancer Center
Image of trial facility.
University Of Missouri - Ellis Fischel

Clinical Trials Christos Papageorgiou is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

More about Christos Papageorgiou

Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Christos Papageorgiou has experience with
  • Biospecimen Collection
  • Questionnaire Administration
  • Paclitaxel
  • No Radiation
  • Radiation
  • Anastrozole

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Christos Papageorgiou specialize in?
Is Christos Papageorgiou currently recruiting for clinical trials?
Are there any treatments that Christos Papageorgiou has studied deeply?
What is the best way to schedule an appointment with Christos Papageorgiou?
What is the office address of Christos Papageorgiou?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security